CDKN2A and central nervous system cancer: This study sought to explore the prevalence of BRAF V600E mutation and CDKN2A deletion in pediatric patients with high-grade glioma (HGG) and aimed to add to the scarce data in the literature about the prognosis of this subset of patients treated with traditional surgery, radiation and chemotherapy.